I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases, and TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, jointly announced that TRACON has dosed the first patient in a U.S. Phase 1 first-in-human clinical trial of I-Mab's proprietary CD73 antibody TJD5, also known as TJ004309, in patients with advanced solid tumors (NCT identifier number: NCT03835949). TJD5 will be dosed in the Phase 1 trial both as a single agent and in combination with TECENTRIQ® (atezolizumab), a PD-L1 antibody marketed by Roche. I-Mab entered into a research collaboration with Roche in April 2019 where Roche agreed to supply TECENTRIQ® to I-Mab for use in clinical study in combination with TJD5.

Multi-Year Project to Analyze Largest Patient Safety Database in the Country and Use Innovative Approach to More Rapidly Identify Actionable Insights

Islam is the second-largest religion in the world and the fastest growing religion in the United States. Certified Registered Nurse Anesthetists (CRNAs) attending the American Association of Nurse Anesthetists (AANA) Annual Congress, August 9-13, 2019, in Chicago will have an opportunity to learn about this religion to help provide culturally competent care to Muslim patients.

Gencurix, Inc., a company dedicated in development and market of innovative molecular diagnostics, announced the publication of a new study on Frontiers in Oncology comparing GenesWell™ BCT, a prognostic multigene test, with Genomic Health's Oncotype DX in patients with early-stage breast cancer.

Collaborative program helps CROs deliver additional value to sponsors with best practices for Patient Data, Patient Experience, Clinical Supplies, and Endpoint Quality Solutions

Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company"), a clinical-stage biopharmaceutical company, today announced dosing of the first patient in its Phase 3 EMERGE efficacy trial of STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine.

According to the American Cancer Society, prostate cancer is the second most common cancer in American men, affecting more than 10 percent of the population.

BD (Becton, Dickinson and Company), a leading global medical technology company, along with Direct Relief and the National Association of Community Health Centers (NACHC) recently honored six community health centers in the U.S. with the "Innovations in Care" award in recognition of their success in low-resource areas identifying and assisting vulnerable people to better manage complex chronic diseases and improve their health.

Harvard-trained, nationally renowned neuropsychiatrist develops Emerging Consciousness Program for children and adults